Exelixis (EXEL) is poised to transform into a multi-faceted oncology company, underpinned by the ongoing success of CABOMETYX and the significant potential of zanzalintinib.

CABOMETYX consistently generates substantial cash flow, providing a solid foundation for the company. Meanwhile, zanzalintinib is anticipated to be a key growth driver, with sales projected to reach an impressive $5 billion by 2033. The company's 2026 revenue guidance of $2.52 billion to $2.62 billion, which does not even include potential contributions from zanzalintinib, reflects a strong financial outlook. This growth is further supported by strategic investments in research and development and ongoing share repurchase programs. My conviction in EXEL remains high, viewing the December 2026 PDUFA date for zanzalintinib as a critical catalyst and observing positive technical momentum for a bullish trajectory.

Exelixis exemplifies the power of strategic development and innovation in the pharmaceutical sector. By leveraging established products while investing in future breakthroughs, companies can achieve sustained growth and make significant contributions to global health. This approach not only promises financial rewards but also reinforces the vital role of research and development in addressing unmet medical needs and improving patient outcomes.